(IN BRIEF) Quest Diagnostics has agreed to acquire select assets from Fresenius Medical Care’s Spectra Laboratories, expanding its portfolio with dialysis-related laboratory and water testing services. This collaboration will enhance the care and efficiency of dialysis services across the U.S., … Read the full press release
Posted in Business, Germany, Healthcare, Pharma & Biotech
Tagged chronic disease care, Chronic kidney disease, dialysis services, end-stage kidney disease, ESKD, Fresenius Medical Care, healthcare partnership, kidney disease diagnostics, laboratory services, Quest Diagnostics, U.S. healthcare, water testing
(IN BRIEF) Evotec and Novo Nordisk’s LAB eN² program, a translational drug discovery accelerator, has selected its first three academic research projects focused on addressing cardiometabolic diseases. The projects, from Boston University, Harvard University in collaboration with Mass General Brigham, … Read the full press release
Posted in Business, Denmark, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged Boston University, Cardiometabolic Research, Chronic kidney disease, Denmark, Dr. Thomas Hanke, Evotec, Harvard University, Joslin Diabetes Center, LAB eN² Program, Mass General Brigham, metabolic syndrome, Novo Nordisk, Obesity, partnership, type 1 diabetes, Uli Stilz
(IN BRIEF) AstraZeneca’s IMPACT CKD model predicts a significant increase in chronic kidney disease (CKD) across eight countries, with up to 16.5% of the population affected by 2032, including a substantial rise in advanced-stage cases. Presented at the 2024 ISN … Read the full press release
(IN BRIEF) Novartis has reported positive interim results from its Phase III ALIGN study involving atrasentan, an oral endothelin A receptor antagonist, for the treatment of IgA nephropathy (IgAN). The study demonstrated that atrasentan significantly reduced proteinuria (excess protein in … Read the full press release
Submission for the treatment of anaemia of chronic kidney disease based on the ASCEND Phase III clinical trial programme, consisting of five trials that all met their co-primary efficacy and safety endpoints EMA file acceptance is the first major regulatory … Read the full press release
Posted in Healthcare, Marketing, News, Pharma & Biotech, United Kingdom
Tagged American Society of Nephrology, anaemia, ASCEND Phase III clinical trial programme, ASCEND-D, ASCEND-ND, Chronic kidney disease, CKD, daprodustat, dialysis, EMA, European Medicines Agency, GlaxoSmithKline, haemoglobin, HIF-PHI, MAA, Marketing Authorisation Application, prolyl hydroxylase inhibitor, treatment of anaemia
(PRESS RELEASE) CAMBRIDGE, 5-Jun-2020 — /EuropaWire/ — British-Swedish multinational pharmaceutical and biopharmaceutical company AstraZeneca announced it will present new data across continuum of care from its broad renal portfolio during the 57th virtual congress of the European Renal Association – … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Society, United Kingdom
Tagged 57th European Renal Association, AstraZeneca, biopharmaceuticals, Chronic kidney disease, European Dialysis, Farxiga, FibroGen, haemodialysis, Hyperkalaemia, Lokelma, renal care, renal medicines, roxadustat, Ruud Dobber, Transplant Association
(PRESS RELEASE) CAMBRIDGE, 26-Mar-2020 — /EuropaWire/ — Science-led biopharmaceutical group AstraZeneca (LSE/STO/NYSE: AZN) has announced that its Lokelma (sodium zirconium cyclosilicate) is now approved in Japan. It is used for the treatment of patients with hyperkalaemia (elevated levels of potassium … Read the full press release
AstraZeneca / BenevolentAI artificial intelligence collaboration will accelerate drug discovery Potential new drugs discovery in the area of chronic kidney disease and idiopathic pulmonary fibrosis (PRESS RELEASE) CAMBRIDGE / LONDON, 30-Apr-2019 — /EuropaWire/ — New partnership, announced today, by AstraZeneca … Read the full press release
Posted in Artificial Intelligence (AI), Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged AI, AI discovery platform, artificial-intelligence, AstraZeneca, Benevolent Platform, BenevolentAI, biomedical knowledge graph, chemistry, Christina Malmberg Hägerstrand, Chronic kidney disease, CKD, clinical data, disease biology, genomics, Gonzalo Viña, idiopathic pulmonary fibrosis, IPF, Jennifer Hursit, Joanna Shields, Machine Learning, Matt Kent, Mene Pangalos, Michele Meixell, pathophysiology of disease, Rebecca Einhorn, Rob Skelding
BIRMINGHAM, 19-Feb-2016 — /EuropaWire/ — New findings from the University of Birmingham show that patients with chronic kidney disease patients and periodontitis (severe gum disease) have a higher mortality rate than those with chronic kidney disease alone. The research, published in … Read the full press release
National award for new University of Leicester research into preventing heart disease in dialysis patients Leicester, UK, 10-2-2014 — /EuropaWire/ — A podcast recording of Dr James Burton explaining his new research project is available to embed and download at: http://soundcloud.com/university-of-leicester/james-burton … Read the full press release
Posted in Awards, Education, Healthcare, Science, United Kingdom
Tagged Chronic kidney disease, dialysis patients, Dr James Burton, heart disease, kidney disease patients, National Institute for Health Research (NIHR) Clinician Scientist Award, preventing heart disease in dialysis patients, Professor David Wynford-Thomas, University of Leicester, University of Leicester research
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?